Literature DB >> 5577482

The choreoathetoid movement disorder induced by levodopa.

C H Markham.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5577482     DOI: 10.1002/cpt1971122part2340

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  14 in total

1.  (+)-PHNO: a new anti-parkinsonian agent which does not induce chorea in MPTP-treated squirrel monkeys.

Authors:  N M Rupniak; S Boyce; M J Steventon; S D Iversen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

Review 2.  Parkinson's disease and levodopa. A five-year follow-up and review.

Authors:  C H Markham; L J Treciokas; S G Diamond
Journal:  West J Med       Date:  1974-09

Review 3.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

4.  A pharmacological study of changes in central nervous system receptor responsiveness after long-term dexamphetamine and apomorphine administration.

Authors:  R C Bailey; D M Jackson
Journal:  Psychopharmacology (Berl)       Date:  1978-04-11       Impact factor: 4.530

5.  [Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].

Authors:  W Gehlen
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1974-04-09

6.  Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.

Authors:  S Boyce; N M Rupniak; M J Steventon; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Relationship between tardive dyskinesia, L-Dopa-induced hyperkinesia and parkinsonism.

Authors:  J Gerlach
Journal:  Psychopharmacology (Berl)       Date:  1977-03-16       Impact factor: 4.530

Review 8.  Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.

Authors:  Tai N Tran; Trang N N Vo; Karen Frei; Daniel D Truong
Journal:  J Neural Transm (Vienna)       Date:  2018-07-03       Impact factor: 3.575

9.  The hyperkinetic syndrome following long-term haloperidol treatment: involvement of dopamine and noradrenaline.

Authors:  D M Jackson; R Dunstan; A Perrington
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

10.  Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.

Authors:  M W Horstink; J C Zijlmans; J W Pasman; H J Berger; M A van't Hof
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-03       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.